3SBio Buys China Rights to Kidney Transplant Drug

3SBio Inc. in-licensed the China rights to voclosporin, a calcineurin inhibitor, from Isotechnika Pharma, a Canadian biopharma. 3SBio will develop the drug to prevent organ rejection following transplant and as a treatment for autoimmune diseases. 3SBio paid $1.5 million in cash and will also make a $4.5 million investment in Isotechnika 3-year convertible debentures. More details.... Stock Symbols: (NSDQ: SSRX) (TSX: ISA)